VivoSeq
Other

Lymphoproliferative Syndrome

6

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Lymphoproliferative Syndrome is an early-stage landscape with 6 programs across 4 companies. The most active players are Roche, Corvus Pharmaceuticals, Inc., AbbVie. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2C

Corvus Pharmaceuticals, Inc.

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Sanofi logo

Sanofi

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

5 of 6 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody117%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 6 pipeline programs.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00013689·8 enrolled
Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00065390·8 enrolled
Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06730126·15 enrolled
Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)
Completed·—·Phase 1/2·NCT00605657·6 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)